Drugs / Anti-STEAP1 CAR T-cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06236139 | Nov 2024 → Mar 2027 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-STEAP1 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06236139 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T (CART)-cell therapy” NCT06236139 ↗ |
| Route | Intravenous | “Given IV” NCT06236139 ↗ |
| Target | STEAP1 | “STEAP1 CART is CAR T cells that have been engineered with a STEAP1 antigen” NCT06236139 ↗ |